FDA Determines Regulatory Review Period for ARRANON Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for ARRANON, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to an application submitted to the Director of Patents and Trademarks, Department of Commerce, for patent extension.